A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

High-street pharmacies are ready to provide the jabs on the NHS and boost take-up for all, says senior pharmacist ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Health service to make medications Mounjaro and Wegovy available after short consultation as part of war on obesity ...

Healthify is banking on the rise of GLP-1 weight-loss drugs in India, integrating them with lifestyle coaching. The firm ...